Targacept, Inc.
Balwinder Bhatti is a master scientist specializing in medicinal and organic chemistry with over 12 years of experience at Targacept, Inc. Expertise includes leading drug discovery and development programs, with a strong focus on innovative solutions for novel small molecules. Prior to the current role, Balwinder served as a senior scientist at Targacept, contributing to discovery chemistry for neurodegenerative diseases and synthesizing novel nicotine-like compounds. Balwinder's academic background includes a Ph.D. in Organic Chemistry from Himachal Pradesh University and postdoctoral research at the University of Kentucky, where significant work involved synthesizing trans-3-hydroxycotinine and nicotine derivatives. Additional experience includes a research associate position at Roswell Park Cancer Institute.
This person is not in the org chart
This person is not in any teams
Targacept, Inc.
Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.